Jaguar’s Napo Secures ESPGHAN Abstracts, Crofelemer Lowers Parenteral Support in Pediatric Patients
Napo Pharmaceuticals, part of Jaguar Health, had two late-breaking abstracts accepted at ESPGHAN demonstrating liquid oral crofelemer reduced parenteral support in pediatric intestinal failure from MVID and SBS. The program holds US and EU orphan drug designations and has completed pediatric MVID trial enrollment with an NDA slated for mid-2027.
1. ESPGHAN Abstract Acceptance
Napo Pharmaceuticals, a family company of Jaguar Health, secured acceptance of two late-breaking abstracts at the 58th Annual ESPGHAN meeting detailing use of liquid oral crofelemer as adjunctive therapy in pediatric intestinal failure due to microvillus inclusion disease and short bowel syndrome.
2. Orphan Drug Designations
Jaguar’s crofelemer program has received orphan drug status in both the US and EU for treatment of MVID and SBS, underscoring regulatory support and expedited pathways for these ultrarare pediatric indications.
3. Pediatric Trial Progress
Enrollment of pediatric MVID patients in a randomized clinical trial is complete. Investigational results show crofelemer adjunctive therapy safely reduced parenteral support needs, with treated patients gaining weight and height over six to twelve months of follow-up.
4. Next Regulatory and Clinical Steps
An NDA filing for pediatric MVID is planned for mid-2027, while adult SBS-IF trials using the same crofelemer formulation continue in Germany, Italy and the US under randomized, double-blind, placebo-controlled protocols.